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African Americans have the highest prevalence of hypertension in the world which may emanate from their predisposition to
heightened endothelial inflammation. The purpose of this study was to determine the effects of a 6-month aerobic exercise training
(AEXT) intervention on the inflammatory biomarkers interleukin-10 (IL-10), interleukin-6 (IL-6), and endothelial microparticle
(EMP) CD62E+ and endothelial function assessed by flow-mediated dilation (FMD) in African Americans. A secondary purpose
was to evaluate whether changes in IL-10, IL-6, or CD62E+ EMPs predicted the change in FMD following the 6-month AEXT
intervention. A pre-post design was employed with baseline evaluation including office blood pressure, FMD, fasting blood
sampling, and graded exercise testing. Participants engaged in 6 months of AEXT. Following the AEXT intervention, all baseline
tests were repeated. FMD significantly increased, CD62E+ EMPs and IL-6 significantly decreased, and IL-10 increased but not
significantly following AEXT. Changes in inflammatory biomarkers did not significantly predict the change in FMD. The change
in VO2 max significantly predicted the change in IL-10. Based on these results, AEXT may be a viable, nonpharmacological method
to improve inflammation status and endothelial function and thereby contribute to risk reduction for cardiovascular disease in
African Americans.

1. Introduction
The most recent report (May 2012) from the World Health
Organization, as well as the preponderance of published
articles on hypertension and race, supports the conclusion
that African Americans have the highest prevalence of

hypertension in the world. Research has demonstrated that
African Americans have a greater prevalence of endothelial
dysfunction when compared to their Caucasian counterparts,
and researchers report that they suspect that this predisposes
them to hypertension [1, 2]. Hypertension is a result of
independent and interactive effects from multiple genetic and
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environmental factors. Inflammation of the endothelium, a
pathological mechanism that can cause endothelial dysfunction and a precursor to hypertension, has been identified as
one of these factors.
It is thought that the balance between pro- and antiinflammation plays a crucial role as a determinant of
endothelial homeostasis and health [3]. Bautista reviewed
multiple studies and reported a positive association between
hypertension and some proinflammatory markers including
C-reactive protein (CRP), interleukin-6 (IL-6), and tumor
necrosis factor alpha (TNF-𝛼) [4]. Experimental evidence
has also established that several proinflammatory cytokines,
including IL-6, contribute to endothelial dysfunction which
may lead to increased peripheral vascular resistance and consequently hypertension [5]. In contrast, interleukin-10 (IL-10)
is a multifunctional cytokine that inhibits activation and the
effector function of T cells, monocytes, and macrophages and
ultimately terminates inflammatory responses [6]. Elevated
circulating levels of IL-10 are associated with improved
endothelial function in individuals with ongoing systemic
inflammation [7] and in coronary artery disease (CAD)
patients [3].
Brachial artery flow-mediated dilation (FMD) is the
conventional method used to assess endothelial function and
health in humans because of its high feasibility as a noninvasive, ultrasound testing modality. Its evaluation is thought to
be an important index in subjects at risk for cardiovascular
disease (CVD) that may contribute to understanding the
extent of the inflammatory status of the endothelium [8]. In
recent years, evidence suggests that endothelial activation,
characterized by increased inflammation, is an early event
in endothelial dysfunction and may be identified with the
endothelial microparticle (EMP) inducible marker CD62E+
which is sensitive to endothelial activation [9]. Experimental
evidence as reported in a review article by Boulanger et
al. suggests that plasma levels of EMPs may be a specific
marker of endothelial dysfunction in patients with CVD
and may provide further information regarding the status
of the endothelium beyond vasodilation [10]. Therefore, the
detection and quantification of EMPs may be a valuable tool
to assess cardiovascular risk.
Increased blood flow shear stress during aerobic exercise has been associated with favorable endothelial adaptations [11]. Additionally, chronic aerobic exercise has been
demonstrated to improve the plasma inflammatory status,
including IL-6 and IL-10, in certain populations. Aerobic
exercise training (AEXT) may lead to the adaptive response
of increasing plasma IL-10 concentrations and decreasing
both plasma IL-6 concentrations and CD62E+ EMPs in
African Americans, thereby improving endothelial function
by reducing inflammation. However, despite the high prevalence of hypertension and CVD in African Americans, few
studies have investigated the effects of AEXT on inflammation and endothelial health in an effort to develop preventive
measures to reduce the CVD disease burden among this highrisk population. Therefore, the purpose of this study was
to determine the effects of a 6-month AEXT intervention
on plasma levels of IL-10, IL-6, and CD62E+ EMPs and
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endothelial function assessed by FMD in a cohort of middleto-older-aged African Americans. Furthermore, a secondary
purpose was to evaluate whether changes in IL-10, IL-6, or
CD62E+ EMPs predicted the change in FMD following the
6-month AEXT intervention.

2. Methods
This study employed a pre-post design following the completion of screening and dietary stabilization. Sedentary,
putatively healthy, middle-to-older-aged (40–75 y/o) African
American men and women were recruited and underwent
a series of screening tests to ensure that they were free of
disease and conditions that may confound interpretation of
results. All qualified participants then completed a dietary
stabilization period in order to control for the effects of
interindividual variations in dietary intake. Finally, any participants using antihypertensive monotherapy were appropriately tapered from their medication, and suspension of
medication was continued for the duration of the study. This
was done to avoid an AEXT by medication interactive effect.
Following dietary stabilization and a minimum of 2 weeks
after medication tapering, baseline testing was conducted.
This included office blood pressure measurements, FMD
studies, fasting blood sampling, and graded exercise testing.
FMD studies and fasting blood sampling were conducted
on separate days but under the same conditions. Upon
completion of baseline testing, participants engaged in a
6-month AEXT intervention under the direct supervision
of laboratory personnel. At the conclusion of the 6-month
intervention, participants repeated all baseline tests.
2.1. Participants. Participants were required to be between
the ages of 40–75 years inclusively, sedentary (self-reported,
regular aerobic exercisers ≤ 2 days per week), nondiabetic
(fasting blood glucose ≤ 126 mg/dL), nonsmoking (≥2 years),
have a clinic blood pressure <160/100 mmHg (i.e., not stage
II hypertensive), and have no documented history of CVD,
hypercholesterolemia (total cholesterol > 240 mg/dL), renal
disease, or pulmonary disease. Participants on lipid lowering
medications, medications that affect cardiovascular or renal
hemodynamics, or who were taking more than one antihypertensive medication were excluded from this study. Both
premenopausal and postmenopausal (self-reported absence
of menses) women were included in the study. All postmenopausal women were required to continue their hormone
replacement therapy, either on or off, for the duration of
the study. These inclusion criteria were used to create a
more homogeneous group of middle-to-older-aged African
Americans who were at low-to-moderate risk for CVD but
who were otherwise putatively healthy. Each participant gave
written informed consent following a complete explanation
of the study during their first laboratory visit. The protocol
was approved by the Temple University Institutional Review
Board.
2.2. Screening. Eligibility of all qualified participants was
ensured via completion of three screening visits prior to
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inclusion in the study. Screening visit one followed a 12hour postabsorptive single blood sampling to assess blood
chemistries and a urinalysis to assess renal function. Any
individual with a total cholesterol >240 mg/dL or fasting
blood glucose >126 mg/dL was excluded from the study.
Estimated glomerular filtration rate (eGFR) was calculated
using the four-variable modification of diet in renal disease
(MDRD) study equation specific to African Americans. Any
participant who exhibited evidence of renal disease (eGFR <
60 mL min−1 per 1.73 m2 ) was excluded from the study.
Screening visits two and three required all qualified
participants to undergo a physician-administered physical
examination and a cycle ergometer echocardiogram stress
test to confirm that participants displayed no evidence of
latent cardiovascular, pulmonary, or other chronic diseases.
2.3. Plasma IL-10 and Plasma IL-6 Concentration. Blood
samples were collected in the morning following a 12hour overnight fast. Blood was drawn into EDTA tubes,
centrifuged at 2,000 g for 20 minutes at 4∘ C, and then the
plasma was frozen at −80∘ C until the time of the assay.
Concentrations of IL-10 and IL-6 were determined using
an enzyme-linked immunosorbent assay (R & D Systems,
Minneapolis, MN, USA). Assays were conducted and analyzed according to manufacturer’s protocol. Absorbance was
recorded using a Spectra Max Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA). The plate was read at 490 nm
with correction for optical imperfections at 650 nm for IL10 and at 450 nm with correction for optical imperfections at
540 nm for IL-6. Intraassay and interassay CVs were 5.5% and
11.9%, respectively, for IL-10 and 7.4% and 4.5%, respectively,
for IL-6.
2.4. CD62E+ Endothelial Microparticles Identification and
Quantification. Circulating EMPs were quantified using a
venous blood sample obtained from the antecubital vein in
the morning following a 12-hour overnight fast. Samples were
collected into EDTA tubes using a 21-gauge needle and were
centrifuged at 2,000 g for 20 minutes at 4∘ C immediately
after collection to separate plasma from whole blood. Plasma
samples were then stored at −80∘ C until measurement.
On the day of analysis, two sequential centrifugation steps
were used to reduce background signals contributed by
plasma proteins and residual contaminating/unwanted cells
and to concentrate microparticles in order to improve the
signal-to-noise ratio during flow cytometric analysis. First,
plasma samples were thawed and centrifuged at 1,500 g for
20 minutes at room temperature to obtain platelet poor
plasma (PPP). The top two-thirds volume of PPP were
then transferred to a new tube and further centrifuged at
1,500 g for 20 minutes at room temperature to obtain cellfree plasma. The supernatant was used for microparticle
analysis. A volume of 100 𝜇L supernatant was incubated
with fluorochrome-labeled antibodies for 20 minutes at room
temperature in the dark and then was fixed by adding 93 𝜇L
of 10% formaldehyde. The mixture was protected from light
and incubated while being gently mixed using a shaker for
20 minutes. The antibody CD62E-PE (15 𝜇L per sample) was
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used to distinguish EMP subpopulations. All antibodies were
obtained from BD Biosciences. After antibody incubation,
samples were diluted with 500 mL of 0.22 𝜇m double-filtered
PBS before flow cytometric analysis. Two additional samples
were also prepared to serve as negative controls and as a
calibration. For the negative control tube, 733 𝜇L of PBS
was added to one tube. The calibrator sample was prepared
using two drops of 0.9 𝜇m standard precision NIST traceable
polystyrene particle beads (Polysciences Inc, Warrington, PA,
USA), and was added to PBS according to the manufacturer’s
instructions. All samples were immediately analyzed by flow
cytometry.
Samples and controls were analyzed using a BDLSRII
flow cytometer (BD Biosciences, San Jose, CA, USA) and
BD FACSDIVA software (v 1.2.6; BD Biosciences). Forward
scatter scale, side scatter scale, and each fluorescent channel
were set in logarithmic scale. Events included in the set gate
(<1.0 𝜇m) were identified in forward and side scatter intensity dot representation and plotted on 2-color fluorescence
histograms. CD62E+ events <1.0 𝜇m were defined as EMPs.
Fluorescence minus one control and nonstained samples
were used to discriminate true events from noise and to
increase the sensitivity for microparticle detection for each
sample. The flow rate was set on medium, and all samples
were run for 180 seconds. Using beads, medium flow rate
was calculated, and a mean sample volume of 101 𝜇L per 180
seconds was processed. EMPs were expressed as events per
𝜇L plasma.
2.5. Brachial Artery Flow-Mediated Dilation. FMD was measured as a percent difference between the diameter of the
brachial artery during basal conditions and the diameter
of the artery following reactive hyperemia. Brachial artery
diameter was measured in response to increased flow. All
measurements were performed in the morning following
a 12-hour overnight fast during which time participants
refrained from food, drink (with the exception of water), caffeine, alcohol, antihistamines, and anti-inflammatory medications. A 7.5 MHz linear phased array ultrasound transducer attached to a Sonos 5500 ultrasound machine (Philips
Medical Systems, Bothell, WA, USA) was used to image the
brachial artery longitudinally. An electrocardiogram (ECG)
was continuously monitored. All measurements of brachial
artery diameter and blood velocity were measured by a
trained cardiologist after the participant rested in a quiet
and dim room at a controlled ambient temperature of 20–
26∘ C for a minimum duration of 10 minutes. The participant’s
right arm was comfortably immobilized in the extended
position to allow for ultrasound scanning of the brachial
artery 5–10 cm above the antecubital fossa. Simultaneous
doppler measurements for blood velocity and 2D ultrasound
imaging for right brachial artery diameter were continuously
recorded for 2 minutes at baseline. After recording of baseline
images, reactive hyperemia was induced by distal occlusion
of the vessel using a cuff inflated to a suprasystolic pressure
(200 mmHg) for 5 minutes on the right forearm and distal
to the antecubital fossa. Brachial artery diameter was then
recorded at 1-minute postcuff release at a fixed distance from
an anatomic marker at the end of diastole.
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2.7. Statistical Analyses. Among the 42 participants who
completed the 6-month AEXT intervention, the data used
in the statistical analysis for each primary outcome variable
were FMD testing (𝑛 = 26), CD62E+ EMPs (𝑛 = 28), IL-6
(𝑛 = 32), and IL-10 (𝑛 = 26). The differences in each variable
sample size are related to issues with participant scheduling,
acquiring blood samples, or assay procedure.
Data are expressed as mean ± the standard error of the
mean (SEM). The distribution of all variables was examined using the Shapiro-Wilk test of normality. Pre-AEXT
and post-AEXT were compared using the paired samples
Wilcoxon signed-rank test. Simple linear regression was used
to calculate relationships between the variables. Statistical
significance was set at a 𝑃 value of <0.05. All statistical
analyses were performed using SPSS version 19.0 (SPSS Inc.,
Chicago, IL, USA).

Brachial artery diameter (cm)

0.40
∗∗

0.39
0.38
0.37
0.36
0.35
0.34
0.33
0.32
0.31
Pre-AEXT
(baseline)

Post-AEXT
(baseline)

Pre-AEXT
Post-AEXT
(1-min
(1-min
post-ischemia) post-ischemia)

(a)
12
∗∗

10
8
FMD (%)

2.6. Aerobic Exercise Training Intervention. A submaximal
graded exercise test was performed to determine participants’ cardiovascular fitness and to develop individualized exercise prescriptions for the AEXT intervention. A
modified Bruce protocol submaximal treadmill exercise test
was performed with continuous measurement of breathby-breath gas sampling oxygen consumption (VO2 ) using
a calibrated metabolic cart (Vmax Encore, SensorMedics,
Yorba Linda, CA, USA). ECG was continuously monitored,
and the treadmill test was terminated when the participant
reached 75–80% of their predicted heart rate reserve. A
standard regression formula using data collected by indirect
calorimetry (VO2 averaged over each 60-second period) and
ECG (minute heart rates) was used to predict VO2 max , a
measure of cardiovascular fitness, as recommended by the
American College of Sports Medicine Guidelines for Exercise
Testing and Prescription.
Participants engaged in a 24-week AEXT intervention
under direct supervision of lab personnel 3x/week, beginning
with 20 minutes of exercise/session at 50% of VO2 max .
Training duration was then increased by 5 minutes each week
until 40 minutes of exercise at 50% of VO2 max was reached.
Training intensity was then increased by 5% each week
until 65% of VO2 max was achieved. At week 8, participants
reached the desired exercise duration and intensity of 40
minutes at 65% of VO2 max , which they maintained as their
prescription for the remainder of the study. Exercise modes
included treadmill walking/jogging, stair stepping, stationary
cycling, rowing ergometry, arm ergometry, and elliptical
cross-training. To monitor exercise intensity, participants
were instructed on how to use heart rate monitors. Study
personnel recorded participants’ exercise mode, heart rate,
and duration in printed logs to ensure adherence to the prescribed exercise training program. Heart rate was recorded
every 10 minutes. At week 12, participants completed a second
submaximal treadmill exercise test as a basis for adjustment
of their exercise prescription to account for changes in
cardiovascular fitness. The gradual progression of training
duration and intensity was used in order to avoid excessive
fatigue and musculoskeletal complaints, thereby maximizing
adherence.
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Figure 1: Measures of brachial artery diameter and endothelial
function before and after AEXT. The upper panel (a) shows brachial
artery diameter at baseline and at 1-minute post-ischemia pre- and
post-AEXT. The lower panel (b) shows FMD% pre- and post-AEXT.
Bars are expressed as mean ± SEM. ∗∗ Denotes significant differences
pre- versus post-AEXT; 𝑃 < 0.01.

3. Results
3.1. Laboratory Values of Participants before and after Exercise
Training. The study group consisted of 42 African American
men (𝑛 = 6; 14.3%) and women (𝑛 = 36; 85.7%). The
mean age of the group was 52.7 ± 1.0 years. The laboratory
values of the participants measured prior and subsequent
to the AEXT intervention are presented in Table 1. The 6month AEXT intervention significantly increased VO2 max
and significantly decreased BMI, plasma triglycerides, and
fasting blood glucose. Total cholesterol, LDL cholesterol,
HDL cholesterol, and mean systolic and diastolic blood
pressure were not significantly changed following the AEXT
intervention.
3.2. Endothelial Function before and after Exercise Training.
Pre- and post-AEXT values of measures obtained from
assessment of endothelial function by FMD testing are
presented in Figure 1. There was a 2.9% increase in baseline
brachial artery diameter (Figure 1(a)) following AEXT; however, this increase was not statistically significant. Brachial
artery diameter 1-minute post-ischemia was significantly
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Table 1: Laboratory values of participants before and after AEXT.
Variable
BMI (kg/m2 )
VO2 max (mL/kg/min)
SBP (mm Hg)
DBP (mm Hg)
Total cholesterol (mg/dL)
LDL cholesterol (mg/dL)
HDL cholesterol (mg/dL)
Triglycerides (mg/dL)
Fasting glucose (mg/dL)

Participant number
𝑛 = 42
𝑛 = 41
𝑛 = 41
𝑛 = 41
𝑛 = 35
𝑛 = 36
𝑛 = 36
𝑛 = 36
𝑛 = 34

Pre-AEXT
31.4 ± 0.9
25.9 ± 0.9
124.2 ± 1.9
78.7 ± 1.1
190.9 ± 4.2
108.7 ± 3.6
66.8 ± 3.3
83.0 ± 5.7
95.1 ± 1.7

Post-AEXT
30.6 ± 0.9∗
28.2 ± 1.1∗∗
123.6 ± 2.2
78.9 ± 1.2
190.4 ± 5.2
111.9 ± 4.3
65.6 ± 3.4
70.1 ± 3.3∗∗
88.5 ± 1.8∗∗

Percent change
−2.5%
8.9%
−0.5%
0.3%
−0.3%
2.9%
−1.8%
−15.5%
−6.9%

Participant number represents usable sample for variables.
Values are expressed as mean ± SEM. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL:
low-density lipoprotein.
∗
Denotes significant differences pre- versus post-AEXT; 𝑃 < 0.05.
∗∗
Denotes significant differences pre- versus post-AEXT; 𝑃 < 0.01.

increased by 5.6% (Figure 1(a)) following AEXT. The relative increase in brachial artery diameter from baseline to
post-ischemia (FMD%) was significantly increased by 60%
(Figure 1(b)) following AEXT.

3.3. Inflammatory Biomarkers before and after Exercise
Training. Pre- and post-AEXT values for the inflammatory
biomarkers are presented in Figure 2. The 6-month AEXT
intervention elicited statistically significant changes in
CD62E+ EMPs and IL-6. There was a significant 47.3%
decrease in CD62E+ EMPs (Figure 2(a)) and a significant
12% decrease in IL-6 (Figure 2(b)) following AEXT. IL-10 was
increased by 4.9% (Figure 2(c)) following AEXT; however, it
was not statistically significant.

3.4. Regression Analyses. Simple linear regression using
change values for each biomarker revealed that changes in
CD62E+ EMPs, IL-10, or IL-6 did not significantly predict the
change in FMD%. Based on the combined 𝑟2 values, CD62E+
EMPs, IL-10, and IL-6 accounted for 10.3% of the change
in FMD%. Simple linear regression demonstrated that the
change in VO2 max significantly predicted the change in IL-10
(𝑛 = 25; 𝑃 = 0.02).

4. Discussion
The primary findings of the present study demonstrated that
6 months of AEXT elicited significant positive improvements
in the inflammatory biomarkers IL-6 and CD62E+ EMPs, as
well as the endothelial function marker FMD in a cohort of
middle-to-older-aged African Americans. Other studies that
measured inflammatory biomarkers and endothelial function
prior to and subsequent to AEXT have demonstrated similar
results, but to our knowledge this is the first study that
measured all of these complementary biomarkers prior to and
subsequent to AEXT in an African American population.

Improvements in FMD following AEXT have been well
documented in previous research. Cornelissen et al. demonstrated a significant increase in FMD% following 12 weeks
of aerobic exercise in stable CAD patients [12]. Similarly,
Luk et al. conducted research to determine the effect of
8 weeks of AEXT on FMD in patients with stable CAD
and demonstrated significant improvements in FMD [13].
Furthermore, Nualnim et al. reported that 12 weeks of regular
swimming exercise in a group of putatively healthy adults
with prehypertension or stage 1 hypertension significantly
improved FMD [14]. However, none of these published
studies included sufficient numbers of African Americans to
draw any conclusions about the effect of AEXT on FMD in
this population. The present study provides some evidence
that AEXT may also be beneficial for improving FMD in
African Americans.
The results of the present study demonstrated that the
change in inflammatory biomarkers CD62E+ EMPs, IL-6,
and IL-10 together accounts for 10.3% of the change in
FMD% following AEXT. These findings suggest that the three
inflammatory biomarkers measured may be contributory
to the health of the endothelium; however, there are other
factors that may also impact overall endothelial health. It is
possible that other biomarkers that were not the focus of
this study such as C-reactive protein, oxidized LDL, vascular
adhesion molecule, or von Willebrand factor may be better
predictors of the change in FMD% with AEXT in this
population.
To our knowledge, the effect of AEXT on CD62E+ EMPs
has not been previously investigated in any population.
CD62E+ EMPs have been identified as markers of inflammatory endothelial cell activation [9, 10, 15, 16]. Therefore,
the detection and quantification of EMPs may be a valuable
marker in the early detection of cardiovascular risk. Lee et al.
demonstrated that a high level of CD62E+ EMPs is associated
with cardiovascular events in patients with a history of stroke,
suggesting that systemic endothelial activation is associated
with the risk for cardiovascular morbidities [17]. The present
study provides some of the first evidence that AEXT may
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Figure 2: Inflammatory biomarkers before and after AEXT. The
upper panel (a) shows CD62E+ EMPs pre- and post-AEXT. The
middle panel (b) shows IL-6 pre- and post-AEXT. The lower panel
(c) shows IL-10 pre- and post-AEXT. Bars are expressed as mean
± SEM. ∗ Denotes significant differences pre- versus post-AEXT;
𝑃 < 0.05. ∗∗ Denotes significant differences pre- versus post-AEXT;
𝑃 < 0.01.

attenuate endothelial activation in African Americans which
may have clinical importance given the recent findings from
Lee et al.
IL-6 is a pleiotropic cytokine whose primary biological
functions include mediation of proinflammatory responses
and cytoprotection [18]. It is released by endothelial cells
in response to inflammatory stress and is essential in the
pathogenesis of vascular inflammatory diseases [19, 20]. A

review of multiple studies by Boos and Lip concluded that
IL-6 contributes to endothelial dysfunction which may lead
to increased peripheral vascular resistance and consequently
hypertension [5]. The effect of AEXT on circulating levels of
IL-6 following AEXT has been previously investigated. Beckie
et al. demonstrated that there were significant reductions in
IL-6 concentrations in women with CAD following a cardiac
rehabilitation exercise program [21]. Additionally, a metaanalysis by Swardfager evaluated changes in inflammatory
biomarkers subsequent to exercise interventions in patients
with CAD and demonstrated significant decreases in plasma
IL-6 concentration [22]. The present study provides further
evidence that AEXT may attenuate plasma IL-6 concentrations, and to our knowledge, demonstrating such for the first
time in an African American population.
IL-10 is an anti-inflammatory cytokine produced by
immune and nonimmune cells [23]. Its primary biological
function is to attenuate inflammatory responses, and it has an
anti-inflammatory effect on monocyte/endothelium interactions [6, 24]. IL-10 has been demonstrated to participate in
preserving endothelial function during acute inflammation
[25]. Although a clear mechanism has not yet been elucidated,
emerging evidence suggests that IL-10 has a role in vascular
protection [23]. Most studies that have measured serum or
plasma IL-10 concentrations have found detectable levels of
IL-10 in a diseased population versus healthy subjects. Blay et
al. measured IL-10 in 153 subjects with non-Hodgkin’s lymphoma and compared them to a control group of 60 healthy
subjects. The researchers found that IL-10 was not detectable
in any of the healthy subjects, but it was detectable in about
half of the diseased subjects [26]. In the present study, the fact
that we were able to detect IL-10 even at relatively low levels in
our putatively healthy African American population may be
interpreted as a result of the increased predisposition in this
population to chronic low-grade inflammation.
Several studies have previously examined the effect of
AEXT on circulating levels of IL-10. Ribeiro et al. examined
the effect of AEXT on the plasma inflammatory status
of post-myocardial infarction patients and concluded that
AEXT increased IL-10, suggesting enhancement of antiinflammation [27]. Furthermore, Goldhammer et al. demonstrated that AEXT in CAD patients was effective in increasing
IL-10, leading to improvements in coronary risk status [28]. In
a review article by Batista et al. on multiple studies of exercise
and IL-10, the authors concluded that the anti-inflammatory
effect induced by AEXT seems primarily to be mediated
by IL-10 [29]. In the present study, the effect of AEXT on
circulating levels of IL-10 was investigated, to our knowledge,
for the first time in an African American population, and
the results demonstrated that there was a trend for increased
IL-10 subsequent to AEXT, although statistical significance
was not achieved. More notably, the results of the present
study indicated that in our African American population
sample, the significant improvement in cardiovascular fitness,
as measured by VO2 max , was related to the improvement in
plasma levels of IL-10. Future research is warranted in order
to assess whether further increases in VO2 max , subsequent to
AEXT, elicit a significant improvement in IL-10.
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We previously reported that African American endothelial cells had significantly greater levels of IL-6 protein expression and produced greater amounts of IL-6 in response to
TNF-𝛼, an inflammatory cytokine [30]. Oxidative stress and
inflammation often occur simultaneously [31]. Kalinowski
demonstrated that African Americans have increased levels
of oxidative stress resulting in endothelial dysfunction when
compared to Caucasians [32], and we also previously demonstrated that compared to Caucasian endothelial cells, African
American endothelial cells had significantly greater protein
expression levels of NADPH oxidase, the principal source
of reactive oxygen species in endothelial cells [33]. Together,
the work of others and our group suggests a heightened
inflammatory and oxidative stress status in African American
endothelial cells. Therefore, an intervention that can dampen
this condition before endothelial dysfunction develops to the
point where it is manifested clinically may be very important.
The results from our present study extend upon our previous
work that AEXT may be a nonpharmacological treatment
modality which may improve endothelial health in middleto-older-aged African American adults free of overt CVD.
The positive changes in endothelial and inflammatory
biomarkers after AEXT demonstrated in this study may
indicate considerable improvement in CVD risk for the
African American population. A substantial portion of the
CVD risk reduction associated with exercise training cannot
be entirely explained by changes in conventional CVD risk
factors [34]. It has been suggested that direct effects of
exercise on the vessel wall may account for some of the
remaining risk factor reduction gap [35].
The participants in the present study had no significant
changes in mean blood pressure following AEXT. These
findings are in agreement with most studies that measured
blood pressure subsequent to AEXT in individuals with
relatively normal resting blood pressure levels. In studies
on normotensive and/or prehypertensive populations, blood
pressure did not significantly change following AEXT in most
cases [36, 37]. Conversely, a review by Hagberg et al. reported
that blood pressure significantly decreased in 75% of the
hypertensive subjects following AEXT [38]. Despite the fact
that mean blood pressure did not change in the present study,
the endothelial and inflammatory biomarkers measured in
this study related to endothelial health and CVD improved
considerably. Therefore, the pronounced benefits on CVD
risk reduction resulting from AEXT may go beyond simple
blood pressure reduction in an African American population
as elucidated by the results of the present study.
Several limitations must be noted when interpreting our
study findings. First, our sample size is small, but this was
due to the exclusion of diabetics, smokers, participants with
CVD, or other chronic diseases and those on medications
that affect cardiovascular or renal hemodynamics, on lipid
lowering medications, or on more than one antihypertensive
medication. This was done to create a more homogenous
group and to ensure lack of confounding variables that
may influence endothelial or inflammatory marker levels. It
should be noted that even with a relatively small sample size,
we observed significant changes in three of the four primary
outcome measures subsequent to AEXT. Second, because of
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the observational nature of the study design, we cannot infer
mechanisms underlying exercise training induced changes
in inflammatory status or endothelial function. Third, there
are presently no standardized methods for the measurement
of microparticles. Processing and analyzing techniques differ from investigator to investigator, and thus comparisons
across studies for EMPs should be done cautiously. Fourth,
no control group was included in the study design, and
thus it is difficult to ascertain whether the observed changes
were exclusively due to AEXT and not to the result of an
unidentified confounding factor. Finally, the sample population was predominately female, and thus our findings may
have limited generalizability to African American males.
In conclusion, the results of the present study are novel
because to our knowledge, for the first time, FMD%, CD62E+
EMPs, IL-6, and IL-10 have been measured together prior to
and subsequent to AEXT in a population of African Americans. The primary findings of the study revealed favorable
alterations in the endothelial and inflammatory biomarkers
measured subsequent to AEXT. Therefore, aerobic exercise
training may be a viable, nonpharmacological method to
improve inflammation status and endothelial function and
thereby contribute to risk reduction for CVD in African
Americans.
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